Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2-breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)UnknownNCT05809024
What this trial is testing

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

Who this might be right for
Locally Advanced Breast CancerHormone Receptor Positive，HER2-negative Breast Cancer
Yongsheng Wang 100
Testing effectiveness (Phase 2)Looking for participantsNCT07732491
What this trial is testing

Culmerciclib in HR+/HER2+ Advanced Breast Cancer

Who this might be right for
Breast CancerMetastastic Breast CancerHER2+ Advanced Breast Cancer
Sun Yat-sen University 35
Early research (Phase 1)Study completedNCT05159518
What this trial is testing

PRT2527 in Participants With Advanced Solid Tumors

Who this might be right for
SarcomaCastrate Resistant Prostate CancerHormone Receptor Positive HER2 Negative Breast Cancer+2 more
Prelude Therapeutics Incorporated 30
Post-approval studies (Phase 4)UnknownNCT05302336
What this trial is testing

AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer

Who this might be right for
Breast CancerChemotherapeutic Toxicity
Second Affiliated Hospital, Zhejiang University, School of Medicine 402
Testing effectiveness (Phase 2)Active Not RecruitingNCT05463601
What this trial is testing

Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 132
Not applicableNot Yet RecruitingNCT07706933
What this trial is testing

Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Henan Cancer Hospital 456
Large-scale testing (Phase 3)Looking for participantsNCT06312176
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 1,200
Testing effectiveness (Phase 2)Study completedNCT05445908
What this trial is testing

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer and HR+/HER2- BC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 184
Testing effectiveness (Phase 2)UnknownNCT05633914
What this trial is testing

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

Who this might be right for
HR+/HER2- Breast Cancer
Hunan Cancer Hospital 90
Large-scale testing (Phase 3)Looking for participantsNCT05212454
What this trial is testing

Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks

Who this might be right for
Breast CancerChemotherapy Effect
Second Affiliated Hospital, Zhejiang University, School of Medicine 400
Testing effectiveness (Phase 2)Study completedNCT03272477
What this trial is testing

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Who this might be right for
Breast Neoplasms
Palleos Healthcare GmbH 257
Not applicableLooking for participantsNCT06650423
What this trial is testing

Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer

Who this might be right for
Early Breast CancerHormone Receptor Positive TumorHER2-negative Breast Cancer
Institute of Oncology Ljubljana 319
Testing effectiveness (Phase 2)Looking for participantsNCT06611813
What this trial is testing

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

Who this might be right for
HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05101096
What this trial is testing

Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Triple-Negative Breast CancerHR+/HER2- Metastatic Breast Cancer+1 more
Gilead Sciences 135
Large-scale testing (Phase 3)Ended earlyNCT00543127
What this trial is testing

Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 870
Testing effectiveness (Phase 2)Ended earlyNCT05176080
What this trial is testing

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Henan Cancer Hospital 46
Not applicableWithdrawnNCT07076680
What this trial is testing

A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer MetastaticHR+/HER2- Advanced Breast Cancer
SciClone Pharmaceuticals
Not applicableStudy completedNCT06619704
What this trial is testing

Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With Chemotherapy

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 194
Testing effectiveness (Phase 2)Looking for participantsNCT05953350
What this trial is testing

A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i

Who this might be right for
Inhibition of Autophagy Synergizes Anti-tumor Effect
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 29
Early research (Phase 1)Looking for participantsNCT06120283
What this trial is testing

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorAdvanced Breast CancerMetastatic Breast Cancer+5 more
BeOne Medicines 433
Next Page